TABLE 5.
Secondary endpoints used as efficacy indicators for the 44 COVID‐19 patients in the experimental group and the control group
| Index | Experimental group | Control group | P |
|---|---|---|---|
| Virus negative time (Mean ± SD, days) | 15.75 ± 13.71 | 18.31 ± 9.86 | .251 |
| Time to improve (Mean ± SD, days) | 3.00 ± 3.05 | 8.80 ± 10.77 | .049 |
| The number of days in hospital (Mean ± SD, days) | 30.65 ± 16.16 | 34.94 ± 18.00 | .413 |
| Stay in ICU (Mean ± SD, days) | 24.00 ± 12.67 | 22.17 ± 20.66 | .465 |
| Shock | 1.000 | ||
| Yes, n (%) | 4 (15.38) | 3 (16.67) | |
| No, n (%) | 22 (84.62) | 15 (83.33) | |
| Multiple organ dysfunction syndrome (MODS) | .128 | ||
| Yes, n (%) | 3 (11.54) | 6 (33.33) | |
| No, n (%) | 23 (88.46) | 12 (66.67) | |
| Rate of chest imaging changes | .049* | ||
| n for check (n for not check) | 20 (6) | 12 (6) | |
| Improvement, n (%) | 17 (85.00) | 6 (50.00) | |
| No change, n (%) | 3 (15.00) | 6 (50.00) | |
| Exacerbation, n (%) | 0 (0.00) | 0 (0.00) |
Note. “n” represents number.
*
Represents significant difference (P < .05).